Literature DB >> 7470730

Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa.

P Bey, M J Jung, J Koch-Weser, M G Palfreyman, A Sjoerdsma, J Wagner, M Zraïka.   

Abstract

1 alpha-Monofluoromethyldopa (MFMD, RMI 71963), a potent and selective enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase produces a substantial and long-lasting decrease in the catecholamine content of mouse brain, heart and kidney. 2 Single doses of MFMD reduce the 5-hydroxytryptamine concentration of mouse brain without altering the tryptophan concentration. 3 In animals treated with MFMD, peripheral but not brain noradrenaline is restored within 1 h to control levels by an intraperitoneal injection of dopamine.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7470730      PMCID： PMC2044376          DOI： 10.1111/j.1476-5381.1980.tb09776.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  8 in total

1.  ELUCIDATION OF THE RATE-LIMITING STEP IN NOREPINEPHRINE BIOSYNTHESIS IN THE PERFUSED GUINEA-PIG HEART.

Authors:  M LEVITT; S SPECTOR; A SJOERDSMA; S UDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1965-04       Impact factor: 4.030

Review 2.  Decarboxylase inhibitors.

Authors:  G Bartholini; A Pletscher
Journal:  Pharmacol Ther B       Date:  1975

3.  alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase.

Authors:  M G Palfreyman; C Danzin; P Bey; M J Jung; G Ribereau-Gayon; M Aubry; J P Vevert; A Sjoerdsma
Journal:  J Neurochem       Date:  1978-10       Impact factor: 5.372

4.  Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with alpha-monofluoromethyldopa.

Authors:  M J Jung; M G Palfreyman; J Wagner; P Bey; G Ribereau-Gayon; M Zraïka; J Koch-Weser
Journal:  Life Sci       Date:  1979-03-12       Impact factor: 5.037

5.  Selective inhibitors of biosynthesis of aminergic neurotransmitters.

Authors:  J Kollonitsch; L M Perkins; A A Patchett; G A Doldouras; S Marburg; D E Duggan; A L Maycock; S D Aster
Journal:  Nature       Date:  1978-08-31       Impact factor: 49.962

6.  Inhibition of peripheral sympathetic function by alpha-monofluoromethyldopa, an irreversible inhibitor of aromatic amino acid decarboxylase [proceedings].

Authors:  J R Fozard; M G Palfreyman; M Spedding; J Wagner; J K Woodward
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

7.  Monamine-depleting properties of a new and very potent enzyme-activated irreversible inhibitor of aromatic aminoacid decarboxylase: alpha-monofluoromethyldopa [proceedings].

Authors:  M J Jung; M G Palfreyman; G Ribereau-Gayon; J Wagner; M Zraïka
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

8.  Determination of dopa, dopamine, dopac, epinephrine, norepinephrine, alpha-monofluoromethyldopa and alpha-difluoromethyldopa in various tissues of mice and rats using reversed-phase ion-pair liquid chromatography with electrochemical detection.

Authors:  J Wagner; M Palfreyman; M Zraika
Journal:  J Chromatogr       Date:  1979-09-11
  8 in total
  2 in total

1.  Alpha-Monofluoromethyldopa (MFMD) in combination with L-DOPA Effects on tissue catecholamines and blood pressure in rats.

Authors:  P Johansson; M Henning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

2.  Cerebral decarboxylation of meta- and para-tyrosine.

Authors:  A A Boulton; A V Juorio
Journal:  Experientia       Date:  1983-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.